Celcuity 3rd Annual Guggenheim Healthcare Innovation Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Okay. Let's get started with our next fireside with Celcuity. My name is Rosy Liao. I am a member of the biotech research team here at Guggenheim Securities. With me, I have Brian Sullivan, CEO and co-founder of Celcuity. Welcome. Great to have you here.
Thank you. My pleasure. To get started, maybe for those who are less familiar with the story, could you provide a quick overview of the company, a high-level view of where you are today, around six weeks into the REVTORPYK launch?
Sure. So, I started the company more than 10 years ago with our chief science officer, with the goal of developing a platform that could quantify the signaling pathway activity of live patient cells taken from patients, with the goal of identifying disease drivers that couldn't be characterized with a genetic assessment. One thing led to another. We had collaborations with Sanofi and Novartis and other drug companies. But we ended up zeroing in on the PI3K/AKT/mTOR pathway, because there was this fundamental question we couldn't answer, which was, how could you have such an important pathway that was implicated in over 40% of tumors with particular mutations, that was clearly a driver metabolically of all tumor cell function, not have an approved drug?
As we dug into this, we characterized using our platform all the drugs that have been developed in this space, to try to understand what, A, was required to induce a treatment effect, and then which drug would you want to work with. We identified a drug, got it's listed now, REVTORPYK, that was owned by Pfizer at the time. Pfizer, we found out as we contacted them and said, "Hey, we'd love to collaborate on this drug," said, "Hey, we've deprioritized this. We are out-licensing it." We raised our hand and were able to strike a deal. The preliminary data was very favorable in second-line breast cancer as well as first-line breast cancer.
We made the decision to proceed almost immediately to a phase III study in breast cancer, where we studied PIK3CA wild-type and PIK3CA mutant patients independently. We received an approval for the PIK3CA wild-type patients. These are second-line HR-positive, HER2-negative advanced breast cancer patients. We began commercializing based on that approval just this past month, or six weeks ago. We have a pending sNDA that will read out with PDUFA end of the second quarter in patients who have a PIK3CA mutation. Both studies were very positive. Then we have two phase III studies underway in the first-line advanced breast cancer setting, one for patients who are less responsive to endocrine treatment, others who are more responsive to endocrine treatment.
Then we recently reported out data in the prostate setting, metastatic castration-resistant prostate patients, that, in our view, was very, very promising and certainly points the way to potential future phase III work. We will be transitioning to a phase II study, essentially do an Optimus study to comply with the FDA guidance, to help us select the phase III dose and accomplish some other goals, which positions us well in, we think, potential expansion into one of the other most significant tumor types. It's not a coincidence that breast cancer and prostate cancer are both very significant potential patient populations we could help, because they're both hormonally driven tumors, estrogen for breast cancer, androgen for prostate cancer. Both involve this pathway, the PAM, as we refer to it, pathway.
Fundamentally, we think our drug is an important driver, and from what we can assess currently, nearly any tumor that has a hormonally driven component. There's a lot of room for us to run currently.
Great. Thanks for that overview. We will be diving into the REVTORPYK launch. You reported earnings recently, and you shared some encouraging early access metrics. You said most of your top strategic accounts are already ordering, and you have broad payer coverage in place. Could you provide any color on what you are seeing on the ground so far, and how do you expect the launch to build over the coming quarters?
Sure. There is a reason why it takes several years to reach peak, because there is a lot of what we view as friction points, being able to get the maximum utilization of your drug in a particular setting. One of them is getting these strategic accounts on board. These strategic accounts treat roughly 50% of available patients. They are complex organizations. They have a lot of requirements to be put in place before they can bring their drug into their system. That is a gate that you need to get lifted. So far, so good. 80% of these strategic accounts are now ordering REVTORPYK. Provider pathways. It is not a well-appreciated requirement, but most systems will incorporate either their own or purchase pathways that serve as almost mini NCCN documents that guide utilization of drugs in their setting. Do they prefer one drug over another?
We have been very successful in getting three of the top four on our side. We are eliminating friction points early on. The reps have been effective in getting access to the doctors and to the accounts, basically introducing them to REVTORPYK, getting some very good early utilization of the drug. There is one other factor which we cannot really control, we can try to mitigate, which is the use of a temporary J-code now, that will ultimately receive a permanent J-code. That will be approved or be given to us in January, will become activated on April 1st. That is a friction point which just takes time. Some accounts are more sensitive to that, more reluctant to bring on drugs with a temporary J-code, and that is just the way it is. Then, of course, you have the treating physicians.
You can think of the treating physician somewhat in a consumer context. You have the experimenters, the early adopters, the mainstream, and then you have the skeptics. Any product, you typically see there is a segmentation based on those behavioral attitudes. Over time, clearly the experimenters, the early adopters will be the ones that drive it initially, and then the mainstream folks who basically want to wait and see, and then the skeptics who eventually win over, we think. We are not projecting any as a percentage. We are just saying that is a typical segmentation growth that you go through. With drugs launched by companies launching their first drug, typically it takes about three years to get to peak penetration for your first launch.
Great. We hope our first-line trials read out positively and we get approvals.
We would expect, because then we will be established a more quick- Right time to peak.
Great. I guess you mentioned the temporary J-code and the permanent code will be coming in April. I guess, can you provide any just like general commentary on kind of how the sites are adapting to the buy-and-bill process currently?
Sure. Every patient in breast cancer, or I should say nearly every patient in breast cancer, will ultimately, either in the first-line setting, second, third, fourth-line setting, receive infused therapy. Infused therapies are distributed through a buy-and-bill approach. This essentially means you get an order from a distributor that goes to our 3PL, and we ship it directly to the site, in our case, next day. So they are very used to working with drugs like ours. They have essentially established centers that are geared towards providing drugs in this manner, and it is an important part of their practices. For a variety of reasons, these drugs become important to these centers financially. So, in many cases, they like to see the patients. It is additional exposure to them to monitor how they are doing. In our case, we have a very, very, we think, significant efficacy advantage over the alternatives.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
